What Is the Default Mode Network?

If you have read any of the recent writing on psilocybin, LSD, MDMA, or ayahuasca, you have probably seen the phrase "default mode network" without quite knowing what it points at. It is one of the most used terms in modern psychedelic neuroscience, and one of the least clearly explained. The default mode network (usually abbreviated DMN) is a specific set of brain regions that activates when the mind is not focused on an external task, when you are daydreaming, self-reflecting, replaying memories, or running internal narration. When a psychedelic takes effect at a meaningful dose, that network goes quiet. That change is consistent enough across substances, doses, and study sites that it is now treated as the most reliable neural signature of the psychedelic state, and the most likely substrate of the ego dissolution that many users describe.

This guide covers what the DMN actually is, where it sits in the brain, what it does in ordinary cognition, how psychedelics suppress it, why that suppression lines up with ego dissolution and the broader therapeutic response, what the clinical evidence says, where the story oversimplifies, and how DMN suppression connects to set, setting, and dose. For the lived-experience side of the dissolution it produces, our What Is Ego Death? guide is the standing companion. For the substance-by-substance dose and effect picture, the Compare Psychedelics hub and the dosage guide give one-page references.

What Is the Default Mode Network?

The default mode network is a set of brain regions that tend to activate together when a person is awake, at rest, and not focused on a demanding external task. It was first characterized in the late 1990s and early 2000s by Marcus Raichle and his collaborators at Washington University in St. Louis, building on PET imaging work that had noticed a consistent pattern: a set of regions used more glucose than expected when subjects lay quietly in a scanner and were not asked to perform any specific task. The network was originally called the "task-negative network" because it deactivated when a person was asked to perform a focused task. The name "default mode" was coined because the network seemed to represent the brain's baseline state, the mode of activity that a person returns to when nothing else is being demanded.

The core anatomical regions of the DMN include the medial prefrontal cortex (a strip running down the inside front of the brain, involved in self-referential thought and social cognition), the posterior cingulate cortex and adjacent precuneus (a region at the back and middle of the brain, heavily involved in autobiographical memory and the sense that there is a self having experiences), the angular gyrus (a parietal region involved in language, memory retrieval, and perspective-taking), and the hippocampal formation (involved in memory consolidation and the recall of past episodes). These regions tend to co-activate and co-deactivate together, which is what defines them as a network rather than a collection of unrelated areas.

The DMN is sometimes described as the brain's "narrator" or "self-referential processor," and those descriptions are serviceable. The network is most active during mental activity that involves the self, memory, future planning, mind-wandering, moral reasoning, and social comparison. When a person is fully absorbed in an external task that requires focused attention, the DMN goes quiet. When that task ends, the DMN comes back online. The same cycling pattern happens during sleep and during the transition out of sleep.

What the DMN Does in the Brain

The DMN is best understood not as a single function but as a coalition of regions that support a related cluster of cognitive activities. Three threads are most central.

Self-referential processing. The medial prefrontal cortex and the posterior cingulate cortex both show increased activity when a person is asked to think about themselves in relation to a stimulus: "Does this word describe me?", "Would I enjoy this?", "How would I feel in this situation?". The same regions activate when a person is thinking about their own past or imagined future, when they are considering how others see them, or when they are reflecting on whether their actions match their values. The DMN is, in a literal sense, the part of the brain that processes "me."

Memory consolidation and retrieval. The hippocampal formation is a core DMN component, and the network as a whole activates during the recall of autobiographical episodes, the integration of new memories with existing ones, and the projection of present experience into imagined future scenarios. This is the cognitive work that makes a person's life feel like a continuous story rather than a sequence of disconnected moments. The DMN is, in another sense, the part of the brain that stitches experience into a narrative.

Mind-wandering and default cognition. When a person is awake but not focused on an external task, the DMN is the dominant active network. This is why the quiet, undemanding moments of a day (lying in bed before sleep, waiting for a bus, sitting in a waiting room) often feel saturated with internal narration: the DMN is doing its main job during those moments. This is also the cognitive mode in which intrusive rumination, worry, and self-criticism tend to run, which is part of why DMN hyperactivity is being investigated in depression, anxiety, and rumination disorders.

A useful summary: the DMN is the network that runs when a person is "in their head" rather than acting on the world. It is most active during self-referential thought, autobiographical memory, and the kind of unstructured inner narration that fills the background of most waking hours.

The DMN and the Sense of Self

The DMN sits in unusually close relation to the experience of being a self. This is not a metaphor. It is a consistent finding across imaging studies that the same network that processes self-referential judgments is also the network that activates during passive rest, autobiographical recall, and the felt continuity of "I" across time.

The sense of self that most adults experience most of the time can be thought of as a construction the DMN actively maintains. It includes a rough model of the body as "mine." It includes a story about personal history and a rough projection into the future. It includes a sense of being a distinct agent looking out at a world. Each of these is supported, in part, by ongoing DMN activity. When DMN activity drops, those constructions thin out in the same order. The body still exists but starts to feel less "owned." Personal history still shows up but feels less like a story happening to "me." The boundary between the perceiver and the perceived starts to feel porous.

This is the structural reason that the DMN is so often at the center of psychedelic neuroscience. The psychedelic state involves, at its core, a dose-dependent loosening of the self-construct that the DMN maintains under ordinary conditions. The two phenomena appear to live in the same neural location and at the same intensity gradients, which is the most consistent mechanistic observation in the modern imaging literature on classic psychedelics.

The same logic applies to meditative traditions that practice sustained non-self-reference. Experienced meditators who practice vipassana, Zen, or certain non-dual traditions show reduced DMN activity during practice, and the reported subjective correlate is a similar sense of boundary softening. The phenomenology is not identical (meditators ordinarily keep awareness intact, and experienced meditators can maintain DMN quieting without dissociation), but the neural pattern overlaps enough that published comparisons treat DMN quieting as a shared substrate.

Why Psychedelics Suppress It

The classic serotonergic psychedelics (LSD, psilocybin, DMT, 5-MeO-DMT, ayahuasca, and mescaline) all act primarily as agonists at the 5-HT2A serotonin receptor subtype. The 5-HT2A receptor is densely expressed on cortical pyramidal neurons in layer V, including in the medial prefrontal cortex and posterior cingulate cortex, both core DMN nodes. When a meaningful dose of a 5-HT2A agonist is on board, those neurons change their firing patterns. The result, visible on fMRI, is a dose-dependent desynchronization within the DMN: regions that normally activate together start to fall out of phase with each other.

The imaging literature on this is unusually consistent. Robin Carhart-Harris and his collaborators at Imperial College London, working with David Nutt and others, ran a series of fMRI and MEG studies on psilocybin between 2012 and the early 2020s using both healthy controls and clinical populations. The signal was stable across studies: psilocybin reduces resting-state functional connectivity within the DMN, increases connectivity between the DMN and other networks that are normally suppressed (the salience network and the visual cortex in particular), and shifts global brain dynamics toward a more entropic, less predictable pattern. The same broad finding has been replicated with LSD by the same group and others, and with DMT and 5-MeO-DMT by related teams.

A parallel literature from Johns Hopkins, led by Roland Griffiths and colleagues, has consistently found that ego dissolution ratings during psilocybin correlate with reduced DMN integration on imaging. The 2016 Carhart-Harris et al. paper in Proceedings of the National Academy of Sciences is probably the most cited single finding in the field: psilocybin-induced ego dissolution was predicted by the magnitude of within-DMN desynchronization, with a correlation that survived correction for dose. PNAS and similar journals have published the broader pattern multiple times since.

The pharmacology story is consistent across the classic tryptamines and phenethylamines: 5-HT2A agonism produces DMN desynchronization, and the magnitude of that desynchronization correlates with the intensity of subjective ego dissolution. The reason that ego death is a class effect across LSD, psilocybin, DMT, 5-MeO-DMT, and ayahuasca rather than a quirk of any one compound is that they share the 5-HT2A mechanism. The differences in duration, intensity, and subjective texture across substances reflect dose, route, half-life, and binding affinity at adjacent receptors, not a fundamentally different neural target. For the dose-by-dose picture across substances, our LSD dosage panel, our psilocybin dosage panel, our DMT dosage panel, and our 5-MeO-DMT dosage panel itemize the bands where DMN suppression converges on ego dissolution in published survey data.

An important adjacent point: ketamine, the dissociative anesthetic, also produces ego dissolution but reaches it through a different mechanism. Ketamine is an NMDA receptor antagonist, primarily acting on glutamatergic signaling rather than 5-HT2A agonism. The published imaging literature on ketamine shows overlapping but distinguishable changes: DMN connectivity reductions are present but smaller in magnitude, and the predominant signal is increased global glutamate flux and a distinct pattern of altered frontoparietal integration. The subjective result is recognizably similar in some respects (boundary softening, dissociation, a K-hole at higher doses), but the neural route gets there through a different pharmacology. For the ketamine-specific picture, our ketamine explainer and our ketamine therapy guide cover the dissociative mechanism in more detail.

DMN Suppression and Ego Dissolution

The same DMN suppression that shows up on imaging during a high-dose experience shows up at the level of subjective experience as a graded softening of the boundary between self and other. As DMN integration falls, the felt continuity of "I" thins; personal history, body image, and social role start to feel more optional; the sense of being a discrete agent looking out at the world loosens. At moderate doses, the effect is a softening. At higher doses, the effect is a dissolution. At the highest reported doses, particularly with inhaled N,N-DMT, 5-MeO-DMT, and high-dose psilocybin or LSD, many users report that the sense of being a self having an experience disappears entirely for the duration of the acute effect.

This is the neural-level bridge to ego dissolution. Our What Is Ego Death? guide covers the lived-experience side in full: what it feels like across substances, what preparation reduces the chance of a difficult experience, what the integration period looks like, and what the published clinical literature says about its role in therapeutic outcomes. The short version of the bridge: ego dissolution and DMN desynchronization live in the same place on the imaging studies, scale with dose in the same direction, and reverse together during the comedown. They are not the same thing; one is a structural brain-state shift and the other is a phenomenological report. They are, however, the closest thing modern psychedelic neuroscience has to a shared mechanism across substances.

For most substances, DMN suppression is dose-dependent. There is no clean threshold; rather, the relationship between dose and within-DMN desynchronization is graded, and the same is true of the relationship between dose and reported ego dissolution. The LSD and psilocybin literature is consistent on this point: at sub-perceptual or low doses, the DMN is mildly desynchronized and ego softening is modest or absent. At common doses (in the ranges tabulated in the dosage guide for each substance), desynchronization is meaningful and ego softening becomes common. At higher doses, the probability of full ego dissolution rises sharply in published survey data.

Setting-dependent factors shift the perceived intensity at any given level of DMN suppression, which is one of the reasons that set, setting, and sitter presence are treated as serious variables in harm reduction and clinical literature. The DMN shift may be comparable across two sessions at the same dose, but the felt result will be reported as more meaningful in a quiet, intentional environment with a trusted sitter, and more frightening in an unfamiliar or unsupervised one. The same neural change, the same dose, but very different phenomenology and very different integration trajectories.

Clinical and Therapeutic Implications

DMN suppression lines up with more than ego dissolution. It also lines up with the broader therapeutic signal in modern psychedelic clinical trials. The pattern runs across psilocybin trials for treatment-resistant depression and major depressive disorder, MDMA-assisted therapy trials for PTSD (now under FDA review), and multiple observational and pilot studies on ayahuasca, LSD, and ketamine for depression, end-of-life anxiety, and addiction.

The most reproduced clinical observation: patients who report a deep felt sense of self-transcendence or ego dissolution during the dosing session tend to report larger clinical gains in the weeks that follow. This pattern shows up across psilocybin trials at Johns Hopkins, Compass, and Usona Institute; in MDMA-assisted therapy trials run by MAPS and its successor organizations; and in the small published ketamine literature. The correlation holds even though it is not the primary endpoint the trials are designed to measure. The DMN imaging literature offers one plausible mechanism: if the rigid, ruminative, self-referential patterns that sustain depressive and anxiety loops are organized in the DMN, then a temporary suspension of that network during the dosing session may open a window in which those patterns are easier to revise. The pattern is consistent enough that the most active hypothesis in the field is that DMN suppression is part of the therapeutic mechanism, not just a side effect.

For the broader clinical picture, our psilocybin and depression deep-dive walks through the published trial evidence, and our ketamine for treatment-resistant depression explainer covers the dissociative-anesthetic version of the same model. The Compare Psychedelics hub places those trials in comparative context across dose, duration, route, and regulatory pathway.

Outside of formal clinical contexts, the same pattern shows up in integration work. Users who report sustained reduction in rumination, looping worry, or rigid self-criticism in the weeks and months after a high-dose session also tend to report that the felt sense of "I" became more porous for a window after the experience. That subjective shift is consistent with a temporary relaxation of the same DMN-organized patterns that produce those loops under ordinary conditions. Integration practices (journaling, talking with a trusted person, time in nature, working with a meditation practice) all engage in different ways with the same region, and the recent picture is that the dosing session opens the window and integration work helps the new pattern settle in.

Risks and the Limits of the Story

The DMN-suppression-as-mechanism story is the most consistent account modern psychedelic neuroscience has, but it is not the whole story, and there are real reasons not to over-read it. This guide has emphasized the parts that hold up, but a balanced picture needs the limits too.

First, DMN suppression is not unique to psychedelics. DMN connectivity reductions also show up during deep meditation, during sleep, during certain seizures, and during the action of several non-psychedelic compounds that do not produce ego dissolution. The mechanism is informative but not specific. It is the combination of 5-HT2A agonism, dose, set, setting, and individual neurochemistry that produces the ego-dissolution phenotype, not DMN desynchronization alone.

Second, individual variability is real and large. The same dose of the same substance can produce very different magnitudes of DMN change across individuals, and published data does not yet support a clean prediction of who will show the largest therapeutic response from any single pre-dose scan. Personality, prior meditation practice, current mood, and acute life context all shape both the imaging result and the subjective outcome. The DMN-suppression story is one substrate, not a deterministic machine.

Third, ketamine reaches an overlapping experiential endpoint through a genuinely different pharmacology. NMDA antagonism and 5-HT2A agonism produce related but distinct neural patterns. Treating ketamine and psilocybin as interchangeable on the basis of "both reduce DMN connectivity" misses the parts of the picture that matter for clinical interpretation and for harm reduction. The dissociative-anesthetic profile of ketamine has its own risk surface (cardiovascular considerations, abuse liability, urinary tract effects at chronic high dose), and the therapy model around ketamine is different from the model around psilocybin. Our ketamine explainer and our ketamine dosage panel cover the dissociative specifics.

Fourth, the imaging literature has its own methodology limits. Most acute-dose fMRI studies are tiny by clinical-trial standards (commonly 10 to 30 participants per condition), and the within-subject design that makes the dose-comparison signal so clean is the same design that limits population-level inference. The published "DMN suppression predicts ego dissolution" result is reliable; it is also drawn from samples that are not representative of the broader population of users, and the predictive claim should be read as a real neural correlation rather than a clean biomarker.

Fifth, none of this changes the medical and psychological cautions around high-dose psychedelic use. SSRIs blunt the effect of serotonergic psychedelics; MAOIs amplify it; lithium combinations have been associated with serious adverse events in published case reports. Anyone taking psychiatric medication should consult a clinician before exploring the dose ranges where DMN suppression produces ego dissolution. Anyone with unmanaged cardiovascular history should be screened out of unsupervised settings. The DMN account is the neural substrate; the safety account is not optional.

Related Reading

The default mode network sits at the intersection of substance effect, dose, set, and setting. To deepen any one of those threads, start with the substance explainer closest to the compound you are exploring:

• What is psilocybin? The most clinically developed 5-HT2A agonist and the cleanest entry point for DMN-suppression research.
• What is LSD? Long duration, sustained DMN desynchronization, and a deep integration tail.
• What is DMT? Abrupt, brief DMN suppression at inhaled doses; longer suppression via ayahuasca.
• What is 5-MeO-DMT? The most pharmacology-distinct tryptamine and the one with the strongest reported correlation between dose and total ego dissolution.
• Ayahuasca The ceremonial brew, its indigenous reciprocity context, and its place in the clinical conversation.
• What is MDMA? Lower DMN-suppression intensity, higher emotional openness, and a separate regulatory pathway.
• What is ketamine? The dissociative anesthetic with its own NMDA-based mechanism for ego dissolution.
• Ketamine for treatment-resistant depression Spravato, IV, and the therapy model around dissociative dosing.
• Microdosing 101 Sub-perceptual dosing well below the DMN-suppression range.

For the lived-experience side of what DMN suppression feels like, see our What Is Ego Death? guide. For dose and effect reference across substances, the dosage guide and the Compare Psychedelics hub are the standing one-page references. For the regulatory picture, the US psychedelic laws map tracks state-level positions. For live events that touch on these themes, the events page lists confirmed and on-radar gatherings.